PDCD1 and cancer: In terms of immunotherapies, immune checkpoint inhibitors (ICIs) are regarded as one of the most crucial counterparts in treating a number of advanced cancers, especially for the application of programmed cell death 1 (PD1) and programmed cell death 1 ligand 1 (PD-L1) inhibitors (3, 6, 8).